Triple-Drug attack on bile duct cancer shows early promise
NCT ID NCT07636798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of three treatments for people with advanced biliary tract cancer that cannot be surgically removed. The approach delivers chemotherapy directly to the liver, along with an immunotherapy drug and a targeted therapy pill. The study aims to find the safest dose and see if the combo can shrink tumors. Only 20 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a combination of chemotherapy (gemcitabine and cisplatin) given directly into the liver, plus an immunotherapy drug (envafolimab) and a targeted therapy pill (lenvatinib)
What this could lead to
If this works, it could offer a new first-line treatment option for people with advanced biliary tract cancer that cannot be removed by surgery.
What could go wrong
This is a very early, small trial (only 20 people) with no comparison group, so results may not apply broadly. The drug combination can cause serious side effects like liver damage or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study Chair Liu Chang , West China Hospital, Chengdu, Sichuan 610041
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••